-
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual MeetingDaiichi Sankyo2023-11-09 20:59:40Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
-
New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and elderly AF patients on LIXIANA (edoxaban) during routine clinical careDaiichi Sankyo2020-09-01 10:19:50New 12-month analysis data from ETNA-AF non-interventional study show low bleeding and ICH rates in frail and
-
NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during 2.5 years of treatmentDaiichi Sankyo2023-11-09 20:59:16NILEMDO® delivers significant cholesterol lowering in addition to statin therapy which is maintained during
-
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights important clinical considerations for treating elderly patients with atrial fibrillationDaiichi Sankyo2023-11-09 20:59:05ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
-
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062Daiichi Sankyo2020-08-03 09:16:13Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi
-
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban treatmentDaiichi Sankyo2023-11-09 14:58:41Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban
-
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-09 20:58:33EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
-
Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across EuropeDaiichi Sankyo2023-11-09 20:56:10Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across Europe
-
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-11-09 20:56:21Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA®
-
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 TrialDaiichi Sankyo2023-11-09 20:56:34ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
